Folic Acid and Hydroxychloroquine Duration in Sickle Cell Disease
Folic acid supplementation is no longer routinely needed in sickle cell disease given widespread food fortification, and hydroxychloroquine (HCQ) is not indicated for sickle cell disease treatment. 1
Folic Acid Supplementation
Current Guideline Recommendation
The American Academy of Pediatrics explicitly states that folic acid supplementation is no longer needed for children with sickle cell disease due to widespread supplementation of formula and grain products in the western world. 1 This represents a significant shift from historical practice.
Evidence Supporting Discontinuation
A 2017 study demonstrated that after stopping folic acid supplementation in 72 patients with severe sickle cell disease, no patients developed red blood cell folate deficiency, and there were no significant differences in hemoglobin levels (P=0.18) or reticulocyte counts (P=0.37) before and after discontinuation. 2
The majority of patients in this study were on hydroxyurea, which extends red blood cell lifespan and reduces folate demands. 2
A 2018 Cochrane systematic review found only one eligible trial from 1983, which showed mixed evidence: while folic acid increased serum folate levels, the effect on anemia and clinical symptoms remained unclear. 3
When Supplementation May Still Be Considered
A 2025 randomized controlled trial in Canadian children found that some children with sickle cell disease may still benefit from daily 1 mg folic acid supplementation, though whether this translates to improved clinical outcomes remains uncertain. 4
If supplementation is prescribed, the standard dose is 1 mg daily taken orally. 3, 5
Important Safety Caveat
Before initiating any folate supplementation, vitamin B12 status must be assessed, as folate can mask B12 deficiency while neurological complications progress. 6 Young Black women with sickle cell disease are at higher risk for pernicious anemia than previously recognized. 6
Hydroxychloroquine (HCQ)
Hydroxychloroquine is NOT a recommended treatment for sickle cell disease. The evidence provided contains no guidelines or research supporting HCQ use in sickle cell disease.
Disease-Modifying Therapies Actually Recommended
The following are the evidence-based disease-modifying treatments for sickle cell disease:
Hydroxyurea: The first-line disease-modifying agent, recommended for every child with HbSS or Sβ⁰-thalassemia starting at 9 months of age, taken once daily indefinitely. 1, 7
Chronic transfusion therapy: Used for stroke prevention (primary or secondary prophylaxis) and select patients with recurrent complications unresponsive to other therapies. 1
L-glutamine (Endari): FDA-approved for reduction of pain events in sickle cell disease. 1
Hematopoietic stem cell transplantation: Curative treatment with best outcomes when performed before age 16 with HLA-matched sibling donor. 1
Common Pitfalls to Avoid
Do not routinely prescribe folic acid without considering that modern food fortification has eliminated deficiency in most patients. 1
Do not prescribe folic acid without checking vitamin B12 levels first, as this can mask pernicious anemia. 6
Do not confuse hydroxychloroquine with hydroxyurea—these are completely different medications with different indications. 1, 7
Do not continue outdated practices from decades ago when nutritional landscapes were different. 1